Oncology Views & Analysis

Views & Analysis

Oncology

Uveal melanoma: A new generation of therapies offers hope fo...

The summer of 2023 saw the approval of a new treatment option for certain patients with uveal melanoma, a form of cancer that begins in the eye and remains a challenge to treat.

Oncology

Resilience, empathy, and gratitude. A personal battle with b...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Nataliya Andreychuk, CEO of Viseven, about her personal battle with breast cancer.

Oncology

ADCs shine at ESMO ’23, as pharma makes case for early immun...

Antibody-drug conjugates (ADCs) took centre stage at the European Society of Medical Oncology (ESMO) Congress in Madrid 20th-24th October, which was back at full capac

Oncology

Where old pathways to innovative cancer care fall short, a n...

Ignoring half the people in the world cannot be good for business.

Oncology

CAR-TCR 2023 – Jonathan Wofford

In order for cell therapies to scale effectively, the industry is clamouring for standardisation around things like manufacturing and treatment administration.

Oncology

The ‘elegant science’ in achieving the promise of ADCs

In this week’s episode of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Raquel Izumi, chief operating officer and co-founder of Vincerx Pharma, who is on a mission to impr

Uveal melanoma: A new generation of therapies offers hope fo...

Resilience, empathy, and gratitude. A personal battle with b...

ADCs shine at ESMO ’23, as pharma makes case for early immun...

Where old pathways to innovative cancer care fall short, a n...

CAR-TCR 2023 – Jonathan Wofford

The ‘elegant science’ in achieving the promise of ADCs

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Views & Analysis

Editor's Picks